Saturday, September 23, 2017 5:26:30 PM
September 23rd, 2017 - Filed Under - by Stacy Sanders
Cantor Fitzgerald reaffirmed their buy rating on shares of Versartis, Inc. (NASDAQ:VSAR) in a report issued on Friday. They currently have a $14.00 price target on the biopharmaceutical company’s stock, down from their previous price target of $34.00.
https://www.dailypolitical.com/2017/09/23/versartis-inc-vsar-given-buy-rating-at-cantor-fitzgerald.html
Eco Science Solutions Integrates IDScan.net's DIVE Into Herbo Pay to Power Identity Verification, Compliance, and Fraud Prevention • ESSI • Mar 27, 2026 12:01 PM
The Crypto Company Acquires FRAME Blockchain's Technology, An "Interstate Highway" Liquidity Layer for Crypto Commerce • CRCW • Mar 26, 2026 12:28 PM
Resilient Energy Inc. Enters LOI Negtiations for Second Acquisition; First Acquisition Nears Closing • RENI • Mar 26, 2026 10:30 AM
Alliance Creative Group (ACGX) Releases 2025 Annual Financial and Disclosure Report • ACGX • Mar 26, 2026 8:30 AM
Isiah Enterprises Activates Scalable Materials Platform Targeting $900B+ Global Market Opportunity; Initiates Strategic Partner Alignment Phase • OWPC • Mar 25, 2026 9:07 AM
ECGI Signs Definitive $25 Million Agreement to Acquire RezyFi • ECGI • Mar 24, 2026 8:30 AM
